On August 28, 2023, amendments to the Drug Enforcement Agency’s (DEA) regulation 21 CFR 1306.08 will go into effect, which brings changes to the laws about the transfer of initial electronic prescriptions for schedule II-V controlled substances between registered retail pharmacies. This adjustment arrives as a result of a Final Rule issued by the DEA on July 27, according to Bass, Berry & Sims.
The move signifies a significant legal shift for registered retail pharmacies in the United States. Until now, the transfer of electronic prescriptions for controlled substances (EPCS) had been strictly regulated, with no provision for these types of transfers between pharmacies. Under the new amendments, registered retail pharmacies will be enabled for a “one-time only” transfer of initial electronic prescriptions for controlled substances.
The DEA responded to comments associated with the amendments when they issued the final rule in July. Detailed in the 88 Federal Register 48365, these responses subsequently resulted in the addition of new subsections (e)-(i) to the regulation 21 CFR 1306.08. These adjustments not only liberalize some of the restrictions around the transfer of controlled substances but also establish a stringent regulatory framework to ensure compliance.
Particularly noteworthy for legal professionals operating in the field of pharmaceutical regulatory affairs, this change provides a good example of the evolving legislative landscape surrounding the digital prescription and distribution of controlled substances. As more and more services within the pharmaceutical sector go digital, it’s expected that further changes to legislation and regulations will continue to be seen.